Compare American Homes 4 Rent Class A (AMH) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Homes 4 Rent Class A vs Merck & Co., Inc. — how do they compare? American Homes 4 Rent Class A trades at $33.74 (market cap $12.28B), while Merck & Co., Inc. trades at $133.52 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 26.2× American Homes 4 Rent Class A's market cap, and American Homes 4 Rent Class A pays the higher dividend (3.87%). Which is the better fit depends on your goals.
| AMH | MRK | |
|---|---|---|
Market Cap | $12.28B | $321.77B |
Sector | Real Estate | Health |
52-Week High | $35.82 | $131.84 |
52-Week Low | $27.38 | $77.60 |
Enterprise Value | $17.35B | $368.53B |
Dividend Yield | 3.87% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMH trades at $34.13, down 1.44% on the day, with a bullish technical signal from moving averages and a consensus price target of $36.45. The company reported strong Q2 2026 earnings, beating FFO and revenue estimates, and raised full-year guidance. Revenue grew to $1.85B in 2025, with net income margin improving to 25.53%. A dividend of $0.33 per share is scheduled for payment on June 30, 2026.
Outlook is positive with consistent earnings beats and raised guidance, but risks include high debt levels and regulatory impacts from new housing legislation. Institutional sentiment remains supportive with no sell ratings among analysts.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Homes 4 Rent Class A
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
